Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University Hospital of Brooklyn
mi
from
Brooklyn, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University Hospital of Brooklyn
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Western New York Health Care System-Buffalo
mi
from
Buffalo, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Western New York Health Care System-Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC - Clifton Park
mi
from
Clifton Park, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC - Clifton Park
mi
from
Clifton Park, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mary Imogene Bassett Hospital
mi
from
Cooperstown, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mary Imogene Bassett Hospital
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York PC-East Syracuse
mi
from
East Syracuse, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York PC-East Syracuse
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Adirondack Cancer Center
mi
from
Glens Falls, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Adirondack Cancer Center
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC - Hudson
mi
from
Hudson, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC - Hudson
mi
from
Hudson, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Orange Regional Medical Center
mi
from
Middletown, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Orange Regional Medical Center
mi
from
Middletown, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nyack Hospital
mi
from
Nyack, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nyack Hospital
mi
from
Nyack, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Champlain Valley Physicians Hospital Medical Center
mi
from
Plattsburgh, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Champlain Valley Physicians Hospital Medical Center
mi
from
Plattsburgh, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC - Rexford
mi
from
Rexford, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC - Rexford
mi
from
Rexford, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Interlakes Foundation Inc-Rochester
mi
from
Rochester, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Interlakes Foundation Inc-Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC - Troy
mi
from
Troy, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC - Troy
mi
from
Troy, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Faxton-Saint Luke's Healthcare
mi
from
Utica, NY
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Faxton-Saint Luke's Healthcare
mi
from
Utica, NY
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cone Health Cancer Center at Alamance Regional
mi
from
Burlington, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cone Health Cancer Center at Alamance Regional
mi
from
Burlington, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Waverly Hematology Oncology
mi
from
Cary, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Waverly Hematology Oncology
mi
from
Cary, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
CaroMont Regional Medical Center
mi
from
Gastonia, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
CaroMont Regional Medical Center
mi
from
Gastonia, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Southeastern Medical Oncology Center - Goldsboro
mi
from
Goldsboro, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Southeastern Medical Oncology Center - Goldsboro
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Wayne Memorial Hospital
mi
from
Goldsboro, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Wayne Memorial Hospital
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
High Point Regional Hospital
mi
from
High Point, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
High Point Regional Hospital
mi
from
High Point, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Kinston Medical Specialists
mi
from
Kinston, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
FirstHealth of the Carolinas-Moore Regional Hosiptal
mi
from
Pinehurst, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
FirstHealth of the Carolinas-Moore Regional Hosiptal
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rutherford Hospital
mi
from
Rutherfordton, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rutherford Hospital
mi
from
Rutherfordton, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Novant Health Forsyth Medical Center
mi
from
Winston-Salem, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Novant Health Forsyth Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Alexius Medical Center
mi
from
Bismarck, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Alexius Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Essentia Health Cancer Center-South University Clinic
mi
from
Fargo, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Essentia Health Cancer Center-South University Clinic
mi
from
Fargo, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sanford Clinic North-Fargo
mi
from
Fargo, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sanford Clinic North-Fargo
mi
from
Fargo, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sanford Medical Center-Fargo
mi
from
Fargo, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sanford Medical Center-Fargo
mi
from
Fargo, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Trinity Cancer Care Center
mi
from
Minot, ND
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Trinity Cancer Care Center
mi
from
Minot, ND
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Cancer Center Beachwood
mi
from
Beachwood, OH
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Cancer Center Beachwood
mi
from
Beachwood, OH
Click here to add this to my saved trials